Midi Health Safety, Regulation & Compliance Posture

What Midi Health Actually Does

Midi Health connects women experiencing perimenopause or menopause symptoms with clinicians through synchronous video visits. The platform accepts several commercial insurance plans and offers cash-pay options for uninsured patients. Visits result in individualized treatment plans that may include FDA-approved menopausal hormone therapy (MHT), non-hormonal alternatives like gabapentin or SSRIs, and lifestyle counseling.

The company was founded in 2020 by Joanna Strober, a health-tech entrepreneur, and has raised over $100 million in venture funding. That venture backing does not itself constitute a safety credential. What matters for patients is whether the clinical model operates within established medical and regulatory guardrails. The answer, based on available public records, is yes. No FDA warning letters appear in the FDA Warning Letters database tied to Midi Health. No state medical board enforcement actions surface in publicly accessible disciplinary databases [1].

Midi's clinical focus is narrow by design. The platform does not treat conditions outside the menopause spectrum. That specialization means clinicians on the platform encounter a concentrated patient population, which can improve pattern recognition and guideline adherence for this specific demographic.

Telehealth Prescribing: The Regulatory Framework

Every telehealth company prescribing medications in the U.S. must manage a patchwork of state-level medical practice acts. Midi Health clinicians hold active licenses in the states where they see patients, a requirement enforced by individual state medical boards and verifiable through each state's license lookup portal [2].

For prescriptions involving controlled substances, the Ryan Haight Online Pharmacy Consumer Protection Act requires at least one in-person evaluation or a valid telemedicine exemption. Most menopausal hormone therapies (estradiol, progesterone, testosterone cream) are not Schedule II-V controlled substances under the DEA's scheduling framework, so this requirement does not apply to the majority of Midi prescriptions. Testosterone, classified as Schedule III, is the notable exception. Midi's prescribing of testosterone follows DEA and state-specific telemedicine rules, including any requirements for an initial synchronous audio-video evaluation [3].

The temporary COVID-era telemedicine flexibilities issued by the DEA have been extended multiple times, most recently through 2025, and replacement rulemaking continues to evolve. Patients considering Midi should verify current DEA telemedicine rules at deadiversion.usdoj.gov for the latest status.

Hormone Therapy Safety: What the Evidence Shows

The safety profile of menopausal hormone therapy itself is the most relevant clinical question for any platform prescribing it. Midi does not manufacture drugs. It prescribes FDA-approved formulations. The safety data therefore rests on decades of trial evidence.

The Women's Health Initiative (WHI), published in JAMA in 2002 (N=16,608 for the estrogen-plus-progestin arm), initially reported increased risks of breast cancer (HR 1.26), coronary heart disease (HR 1.29), and stroke (HR 1.41) in postmenopausal women using conjugated equine estrogen plus medroxyprogesterone acetate [4]. That trial reshaped prescribing patterns worldwide. Millions of women discontinued HRT.

Subsequent reanalysis told a more nuanced story. The WHI's own age-stratified data, published in JAMA in 2007, showed that women aged 50 to 59 who initiated estrogen-only therapy had a non-significant trend toward reduced coronary events (HR 0.63 to 95% CI 0.36 to 1.08) and no increase in breast cancer over 7.2 years of follow-up [5]. The "timing hypothesis," now well-supported, holds that HRT initiated within 10 years of menopause onset or before age 60 carries a meaningfully different risk profile than HRT started in older women.

The 2022 NAMS position statement affirms that for symptomatic women under 60 or within 10 years of menopause, the benefits of HRT generally outweigh the risks [6]. The Endocrine Society's 2015 clinical practice guideline similarly supports MHT for vasomotor symptoms in this population and recommends transdermal estradiol over oral formulations to minimize thrombotic risk [7].

Midi's published clinical protocols, based on publicly available information, align with this evidence base. The platform states it follows NAMS guidelines and uses transdermal estradiol as a first-line option, consistent with the Endocrine Society's recommendation to reduce venous thromboembolism risk associated with oral estrogen [7].

Compounded Hormones: A Compliance Gray Area

Midi Health, like many menopause-focused telehealth platforms, prescribes compounded bioidentical hormones in certain cases. This is where regulatory scrutiny intensifies.

The FDA has repeatedly stated that compounded drugs are not FDA-approved and that "bioidentical" is a marketing term, not a regulatory classification. The FDA's 2020 statement on compounded bioidenticals warns that these products have not undergone premarket review for safety, efficacy, or manufacturing quality [8]. The American College of Obstetricians and Gynecologists (ACOG) recommends FDA-approved hormone products over compounded alternatives when an FDA-approved option exists [9].

Compounded hormones occupy a legal gray zone. Section 503A of the Federal Food, Drug, and Cosmetic Act permits pharmacies to compound medications based on valid prescriptions, provided they meet specific conditions including not compounding drugs that are "essentially copies" of commercially available products [8]. Some states impose additional restrictions.

Midi's use of compounded hormones appears limited to cases where FDA-approved formulations do not meet a patient's clinical needs (e.g., specific testosterone dosing for women, for which no FDA-approved product exists). This practice is common across menopause medicine and is not unique to Midi. Patients should still ask whether an FDA-approved alternative exists before accepting a compounded prescription.

HIPAA Compliance and Data Security

As a telehealth provider handling protected health information (PHI), Midi Health operates as a HIPAA-covered entity. The company uses encrypted video platforms for visits and maintains Business Associate Agreements (BAAs) with its EHR, pharmacy, and laboratory partners. The HHS Breach Portal, which lists breaches affecting 500 or more individuals, does not show any entries for Midi Health as of May 2026.

HIPAA compliance is a floor, not a ceiling. The platform collects sensitive health data about menopause symptoms, sexual health, mood changes, and hormone levels. Patients should review Midi's privacy policy for details on data sharing with third parties, analytics providers, and advertising platforms. A 2023 FTC enforcement action against telehealth company Cerebral for sharing PHI with advertising platforms via tracking pixels illustrates the risk in this sector [10]. No similar action has been taken against Midi, but the precedent underscores why scrutiny is warranted.

How Midi Compares to Alternatives

Several telehealth platforms compete in the menopause care space, including Evernow, Alloy Health, and Gennev (acquired by Unified Women's Healthcare). Traditional in-person options include NAMS-certified menopause practitioners, who can be located through the NAMS provider directory.

The key differentiators among these options are clinician credentialing, guideline adherence, insurance acceptance, and prescribing scope. Midi's insurance acceptance is broader than most direct-to-consumer competitors, which operate predominantly on cash-pay models. Evernow, for example, charges a monthly membership fee that does not include insurance billing.

From a safety standpoint, the most meaningful comparison is between telehealth menopause care and in-person care with a NAMS-certified practitioner. Only about 1,200 providers hold active NAMS certification in the U.S. [11]. That scarcity means most women lack local access to a menopause specialist. Telehealth platforms fill a legitimate access gap, provided the clinicians on those platforms follow the same evidence-based guidelines as in-person specialists.

A 2020 Menopause Society survey found that only 31.8% of OB-GYN residency programs included a formal menopause curriculum [11]. The average primary care physician receives minimal training in menopause management. A telehealth clinician who sees menopause patients exclusively may, in practice, have more concentrated experience than a generalist PCP. That does not guarantee superior care, but the assumption that in-person always equals better is not supported by the data.

Red Flags to Watch For

No platform is immune from risk. Patients evaluating Midi Health (or any menopause telehealth provider) should watch for specific warning signs.

Prescribing without adequate history-taking is the most significant safety concern. Hormone therapy requires assessment of breast cancer risk (family history, BRCA status), cardiovascular risk factors, liver function, and thrombotic history. A visit that lasts under 15 minutes and results in a hormone prescription should raise questions. NAMS recommends individualized risk-benefit assessment before initiating MHT [6].

Overprescribing compounded formulations when FDA-approved alternatives exist is another concern. Pellet therapy (subcutaneous hormone pellets), which some clinics promote aggressively, is not recommended by NAMS or the Endocrine Society due to the inability to adjust dosing after implantation and the risk of supraphysiologic levels [6]. Midi does not appear to offer pellet therapy, which is a positive indicator.

Failure to monitor therapy is a third risk area. NAMS recommends follow-up within 6 to 12 weeks of initiating or adjusting MHT, with annual reassessment thereafter [6]. Patients should confirm that Midi's care model includes these touchpoints.

Clinician Credentialing and Oversight

Midi's publicly stated model involves board-certified physicians and certified nurse practitioners or physician assistants. Each clinician must hold a valid, unrestricted license in the state where the patient resides. Patients can independently verify any Midi clinician's license through their state medical board or nursing board website.

The platform operates under a collaborative physician model in states that require nurse practitioner supervision. The specifics of this arrangement vary by state law. In full-practice-authority states (28 states plus DC as of 2025), nurse practitioners can prescribe independently [12]. In restricted-practice states, a supervising physician must be involved.

One structural advantage of a platform-based model is standardized clinical protocols. Unlike a solo practitioner who may rely on individual judgment, platform clinicians typically follow protocol sets aligned with published guidelines. Midi has stated that its protocols are developed in collaboration with menopause specialists and updated as guidelines change. The 2022 NAMS position statement and 2023 Endocrine Society updates on testosterone therapy in women are the current benchmarks [6][7].

State Availability and Licensing Gaps

Midi does not operate in all 50 states. Telehealth licensing requirements vary significantly, and some states impose restrictions that limit out-of-state telehealth practice. The Interstate Medical Licensure Compact (IMLC) covers 43 member states and territories, streamlining multi-state licensing for physicians [2]. Nurse practitioners have a separate compact (NLC) with its own membership roster.

Patients in states where Midi is not available may need to seek alternatives. The NAMS practitioner directory remains the best resource for locating a credentialed in-person specialist [11].

The Bottom Line on Safety

Midi Health operates within the standard regulatory framework for U.S. telehealth: state-level medical licensing, HIPAA compliance, and DEA rules for controlled substances. Its clinical model aligns with current NAMS and Endocrine Society guidelines for menopausal hormone therapy. No enforcement actions, warning letters, or significant data breaches appear in public records.

The primary risk factors for patients are the same as with any telehealth HRT provider: inadequate initial risk assessment, over-reliance on compounded formulations, and insufficient follow-up monitoring. Patients should verify their Midi clinician's license independently, confirm that a thorough history and risk assessment precede any prescription, and request FDA-approved formulations as a default before accepting compounded alternatives. Annual mammography per USPSTF guidelines remains indicated for women on combination estrogen-progestogen therapy, regardless of prescribing channel [13].